食管腺癌：我们如今处于什么状况？
Oesophageal Adenocarcinomas: Where Do We Stand Today?
作者信息
Karstens Karl-Frederick, Stüben Björn Ole, Reeh Matthias
机构信息
Department of General, Visceral and Thoracic Surgery, University Medical Center Hamburg-Eppendorf, 20246 Hamburg, Germany.
出版信息
Cancers (Basel). 2020 Dec 31;13(1):109. doi: 10.3390/cancers13010109.
Abstract
Oesophageal cancers (oesophageal squamous cell carcinomas and adenocarcinomas) haven been responsible for more than one million deaths worldwide in 2018 [...].
摘要
2018年，食管癌（食管鳞状细胞癌和腺癌）在全球造成了超过100万人死亡[……] 。
你提供的原文中“haven been”表述有误，正确的应该是“have been” 。
相似文献
1
Oesophageal Adenocarcinomas: Where Do We Stand Today?食管腺癌：我们如今处于什么状况？
Cancers (Basel). 2020 Dec 31;13(1):109. doi: 10.3390/cancers13010109.
2
Telomerase activity and patient survival after surgery for gastric and oesophageal cancer.胃癌和食管癌手术后的端粒酶活性与患者生存率
Eur J Gastroenterol Hepatol. 2001 Aug;13(8):903-8. doi: 10.1097/00042737-200108000-00005.
3
Barrett's adenocarcinomas resemble adenocarcinomas of the gastric cardia in terms of chromosomal copy number changes, but relate to squamous cell carcinomas of the distal oesophagus with respect to the presence of high-level amplifications.巴雷特腺癌在染色体拷贝数变化方面类似于贲门腺癌，但就高水平扩增的存在而言，与远端食管鳞状细胞癌相关。
J Pathol. 2003 Feb;199(2):157-65. doi: 10.1002/path.1260.
4
Are carcinomas of the cardia oesophageal or gastric adenocarcinomas?贲门癌是食管腺癌还是胃腺癌？
Eur J Cancer. 2003 Nov;39(17):2487-94. doi: 10.1016/s0959-8049(03)00664-6.
5
Oesophageal and gastric cardia adenocarcinomas: analysis of regional variation using the Cancer Incidence in Five Continents database.食管和贲门腺癌：利用《五大洲癌症发病率》数据库进行区域差异分析
Int J Epidemiol. 2001 Dec;30(6):1415-25. doi: 10.1093/ije/30.6.1415.
6
Comparison of comorbidity prevalence in oesophageal and gastric carcinoma patients: a population-based study.食管癌和胃癌患者合并症患病率的比较：一项基于人群的研究。
Eur J Gastroenterol Hepatol. 2004 Jul;16(7):681-8. doi: 10.1097/01.meg.0000108331.52416.f1.
7
Increased incidence of adenocarcinomas at the gastro-oesophageal junction in Dutch males since the 1990s.自20世纪90年代以来，荷兰男性胃食管交界处腺癌的发病率有所上升。
Eur J Gastroenterol Hepatol. 2002 Feb;14(2):115-22. doi: 10.1097/00042737-200202000-00004.
8
New classification of oesophageal and gastric carcinomas derived from changing patterns in epidemiology.基于流行病学变化模式的食管癌和胃癌新分类
Br J Cancer. 1999 May;80(5-6):834-42. doi: 10.1038/sj.bjc.6690429.
9
The ultrastructure of oesophageal carcinomas: multidirectional differentiation. A transmission electron microscopic study of 43 cases.食管癌的超微结构：多向分化。43例病例的透射电子显微镜研究。
J Pathol. 1992 Jun;167(2):193-8. doi: 10.1002/path.1711670206.
10
Expression signatures and roles of MicroRNAs in human oesophageal adenocarcinomas.人食管腺癌中 MicroRNAs 的表达特征和作用。
J Cell Mol Med. 2018 Jan;22(1):123-130. doi: 10.1111/jcmm.13300. Epub 2017 Aug 10.
引用本文的文献
1
High Serum Levels of Wnt Signaling Antagonist Dickkopf-Related Protein 1 Are Associated with Impaired Overall Survival and Recurrence in Esophageal Cancer Patients.血清中Wnt信号拮抗剂Dickkopf相关蛋白1水平升高与食管癌患者总生存期受损和复发相关。
Cancers (Basel). 2021 Oct 4;13(19):4980. doi: 10.3390/cancers13194980.
2
CT Body Composition of Sarcopenia and Sarcopenic Obesity: Predictors of Postoperative Complications and Survival in Patients with Locally Advanced Esophageal Adenocarcinoma.肌少症和肌少症肥胖的CT身体成分：局部晚期食管腺癌患者术后并发症和生存的预测因素
Cancers (Basel). 2021 Jun 11;13(12):2921. doi: 10.3390/cancers13122921.
本文引用的文献
1
RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV.RACE 试验：新辅助放化疗对比化疗用于局部进展期可切除胃食管结合部腺癌患者——德国肿瘤学会、德国胃肠道肿瘤学会和德国放射肿瘤学会联合开展的一项 III 期随机研究
BMC Cancer. 2020 Sep 15;20(1):886. doi: 10.1186/s12885-020-07388-x.
2
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.帕博利珠单抗或帕博利珠单抗联合化疗对比单纯化疗用于一线晚期胃癌患者的疗效和安全性：KEYNOTE-062 期随机临床研究。
JAMA Oncol. 2020 Oct 1;6(10):1571-1580. doi: 10.1001/jamaoncol.2020.3370.
3
Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival.食管腺癌的抗炎微环境对生存有负面影响。
Cancer Immunol Immunother. 2020 Jun;69(6):1043-1056. doi: 10.1007/s00262-020-02517-8. Epub 2020 Feb 25.
4
Mediastinal Nodal Involvement After Neoadjuvant Chemoradiation for Siewert II/III Adenocarcinoma.新辅助放化疗治疗 Siewert II/III 型腺癌后纵隔淋巴结受累。
Ann Thorac Surg. 2019 Sep;108(3):845-851. doi: 10.1016/j.athoracsur.2019.04.024. Epub 2019 May 15.
5
Pathogenesis and Cells of Origin of Barrett's Esophagus.巴雷特食管的发病机制和起源细胞。
Gastroenterology. 2019 Aug;157(2):349-364.e1. doi: 10.1053/j.gastro.2019.03.072. Epub 2019 May 10.
6
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial.氟尿嘧啶+亚叶酸、奥沙利铂和多西紫杉醇与氟尿嘧啶或卡培他滨+顺铂和表柔比星用于局部晚期可切除胃或胃食管交界处腺癌的围手术期化疗（FLOT4）：一项随机、2/3 期试验。
Lancet. 2019 May 11;393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1. Epub 2019 Apr 11.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018：GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.CheckMate-032 研究：纳武利尤单抗和纳武利尤单抗联合伊匹单抗治疗转移性胃食管交界部癌患者的疗效和安全性。
J Clin Oncol. 2018 Oct 1;36(28):2836-2844. doi: 10.1200/JCO.2017.76.6212. Epub 2018 Aug 15.
9
Clinical Utility of the Combined Positive Score for Programmed Death Ligand-1 Expression and the Approval of Pembrolizumab for Treatment of Gastric Cancer.程序性死亡配体-1 表达联合阳性评分在帕博利珠单抗治疗胃癌中的临床应用价值。
Arch Pathol Lab Med. 2019 Mar;143(3):330-337. doi: 10.5858/arpa.2018-0043-OA. Epub 2018 Jul 20.
10
Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.帕博利珠单抗单药治疗既往治疗的晚期胃和胃食管结合部癌患者的安全性和疗效：Ⅱ期 KEYNOTE-059 临床试验。
JAMA Oncol. 2018 May 10;4(5):e180013. doi: 10.1001/jamaoncol.2018.0013.
Zotero 插件